Nurix Therapeutics, Inc.: Form 10-Q for the period ended May 31, 2023
Filed with the SEC on Jul 13, 2023 and accepted by EDGAR at Jul 13, 2023, 16:19 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-05-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2023-03-01 to 2023-05-31 | $45.8m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2022-12-01 to 2023-05-31 | $91.6m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2023-03-01 to 2023-05-31 | −$26.8m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2022-12-01 to 2023-05-31 | −$69.7m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2023-03-01 to 2023-05-31 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2022-12-01 to 2023-05-31 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2023-03-01 to 2023-05-31 | −$24.3m | us-gaap:NetIncomeLoss |
| Net income | 6 months2022-12-01 to 2023-05-31 | −$65.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2023-03-01 to 2023-05-31 | −$0.45 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2022-12-01 to 2023-05-31 | −$1.20 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2023-03-01 to 2023-05-31 | −$0.45 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2022-12-01 to 2023-05-31 | −$1.20 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2023-03-01 to 2023-05-31 | 54,259,045 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2022-12-01 to 2023-05-31 | 54,144,909 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2022-12-01 to 2023-05-31 | −$66.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2022-12-01 to 2023-05-31 | $3.4m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2023-05-31 | $59.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-05-31 | $290.0m | us-gaap:AssetsCurrent |
| Total assets | At period end2023-05-31 | $350.6m | us-gaap:Assets |
| Current liabilities | At period end2023-05-31 | $72.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-05-31 | $90.7m | us-gaap:Liabilities |
| Shareholders' equity | At period end2023-05-31 | $259.9m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001549595-23-000040. Last ingested by Listed: Nov 5, 2026, 13:59 ET. Listed shows no prices and gives no investment advice.